Saladax, CESAR Partner on Study of 5-FU Dosing for Colorectal Cancer
February 13, 2012
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Saladax Biomedical announced today a collaborative study of metastatic colorectal cancer patients treated with 5-fluorouracil, or 5-FU, and whose doses will be optimized based on actual 5-FU blood levels.
As part of the collaboration with the Central European Society for Anticancer Drug Research, or CESAR, Saladax’s My5-FU immunoassay technology will be used to measure 5-FU levels.
CESAR is sponsoring the single-arm study, which is designed “to determine whether target blood levels of 5-FU can be maintained during the course of treatment by optimizing the dose administered to individual patients at each infusion,” the Bethlehem, Penn.-based company said in a statement. The two partners aim to achieve a stable target blood level of the chemotherapeutic and investigate whether this dose optimization can reduce 5-FU-related toxicities.
Financial and other terms of the deal were not disclosed.
The study, which involves four centers and will enroll 80 patients with metastatic colorectal cancer, is expected to last one year. Patients will remain in the study until a total of six doses of 5-FU treatment has been administered and the end-of-treatment visit has been conducted, Saladax said.